Universal CTC Probe Using Modified SV40 Virus Capsid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting circulating tumor cells (CTCs) in the blood are inefficient, costly, and often fail to capture a significant fraction of CTCs due to the lack of specific surface markers and the heterogeneous nature of tumor cells.
Innovation Solution
Development of a novel universal probe, CTC-UniPro, which uses a modified SV40 virus packaged into a capsid formed from L1 and L2 capsid proteins of human or bovine papillomavirus, combined with a marker gene such as GFP or luciferase, to selectively enter and amplify within CTCs, thereby enhancing detection sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immuno-based capture methods using anti-EpCAM antibodies are used to detect CTCs, then CTC enrichment is achieved, but the method is cumbersome, costly, and captures only a small fraction of CTCs due to tumor cell heterogeneity
Solution Approach 1:
The patent applies universality by developing a detection method that does not rely on specific tumor surface markers like EpCAM. Instead, it uses the universal physical property of size difference between CTCs and blood cells, making the method applicable to all tumor types regardless of their marker expression status, thus resolving the limitation of immuno-based methods that capture only a small fraction of heterogeneous CTCs
Solution Approach 2:
The patent replaces the complex immunochemical system (antibody conjugation, magnetic capture, multiple staining steps) with a simpler physical separation system based on size-based filtration and acoustic manipulation. This substitution eliminates the need for complex reagents and multiple processing steps while maintaining high CTC capture efficiency
2Quantity of substance
If physical property-based isolation methods exploiting CTC size are used, then CTC enrichment is achieved, but many blood cells similar in size or larger than CTCs are not separated
Solution Approach 1:
The patent applies local quality by creating a size-selective filtration system with precisely controlled pore sizes that target the specific size range of CTCs. The filter pores are designed to be slightly larger than normal blood cells but smaller than CTCs, allowing selective passage of blood cells while retaining CTCs, thus achieving both high enrichment and high separation accuracy
Solution Approach 2:
The patent employs dynamic acoustic forces using surface acoustic waves to manipulate cell positioning and enhance separation. The acoustic field dynamically adjusts to apply forces that push larger CTCs toward collection regions while allowing smaller blood cells to pass through, improving separation accuracy without compromising enrichment efficiency
3Measurement precision
If multiple confirmation steps including DAPI staining, cytokeratin staining, and anti-CD45 staining are performed, then CTC identification accuracy is improved, but the detection process becomes more cumbersome and costly
Solution Approach 1:
The patent extracts the essential identification function from the complex multi-step staining process. By using size-based physical separation that inherently isolates CTCs from blood cells based on their size difference, the method eliminates the need for multiple confirmatory staining steps, achieving both high identification accuracy and operational simplicity
Solution Approach 2:
The patent uses physical size as a surrogate marker that copies the identification function of multiple biochemical markers. Instead of detecting multiple specific proteins through staining, the system uses the universal physical property of size, which naturally distinguishes CTCs from blood cells, thereby simplifying the detection process while maintaining accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CTC-UniPro achieves highly sensitive and specific detection of CTCs, even at low concentrations, and can differentiate between tumor cells and normal blood cells, potentially leading to earlier cancer diagnoses and improved treatment strategies.
Implementation Method 1
a modified SV40 virus packaged into a capsid formed from L1 and L2 capsid proteins of human or bovine papillomavirus, combined with a marker gene such as GFP or luciferase, to selectively enter and amplify within CTCs
Implementation Method 2
packaged into a capsid formed from L1 and L2 capsid proteins of human or bovine papillomavirus
Implementation Method 3
a marker gene such as GFP or luciferase
Implementation Method 4
a marker gene such as GFP or luciferase
Data Source
AI summary
Disclosed are probes based on papilloma virus and modified SV40 comprising a green fluorescent protein marker gene that can be used for detecting circulating tumor cells (CTCs) in the blood stream, methods for manufacturing such probes, and methods for using such probes.